MetaCap

Intellia Therapeutics (NTLA) vs Alpha Teknova (TKNO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alpha Teknova (TKNO) has outperformed Intellia Therapeutics (NTLA) over the past year, gaining 77.4% versus a gain of 21.8%. Over five years, TKNO leads with a -63.6% price change compared with -91.2% for NTLA. Intellia Therapeutics is the larger company by market cap ($1.40 billion vs $480.0 million), about 2.9 times the size.

Alpha Teknova converts more of its revenue into profit, with a net margin of -42.6% versus -609.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NTLA+21.80%TKNO+77.44%
+126%+32%-62%
Nov 21, 20251 yearNov 20, 2026
NTLA-92.28%TKNO-69.50%
+5%-48%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NTLA versus TKNO key metrics
MetricNTLATKNO
Share price$10.00$7.63
Market cap$1.40B$479.95M
1-day change+5.04%-2.30%
YTD return+11.23%+100.79%
1-year return+21.80%+77.44%
5-year return-91.16%-63.63%
EPS (TTM)$-3.35$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$67.67M$40.52M
Revenue growth (YoY)+16.92%+7.35%
Net income (latest FY)$-412.69M$-17.26M
Gross margin—33.17%
Operating margin-651.67%-41.90%
Net margin-609.85%-42.59%
52-week high$18.48$9.48
52-week low$8.09$1.91
Distance from 52-week high-45.89%-19.51%
Analyst consensusbuynone
Avg. price target upside+127.80%+28.83%
Average volume5.03M437.31K
Shares outstanding140.36M62.90M
Employees377158
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Intellia Therapeutics is about 2.9 times larger than Alpha Teknova by market value ($1.40B vs $479.95M).
  • TKNO has outperformed NTLA by 55.6 percentage points over the past year.
  • Alpha Teknova is more profitable, keeping -42.6 cents of every revenue dollar as net income versus -609.9 cents for Intellia Therapeutics.
  • Intellia Therapeutics grew revenue faster in its latest fiscal year (+16.92% vs +7.35%).

About Intellia Therapeutics

NTLA stock →

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees

About Alpha Teknova

TKNO stock →

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees

NTLA vs TKNO FAQ

Which is bigger, Intellia Therapeutics or Alpha Teknova?

Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.40B compared with $479.95M for Alpha Teknova (TKNO).

Which stock has performed better over the past year, NTLA or TKNO?

TKNO returned +77.44% over the past 12 months, compared with +21.80% for NTLA (price return, excluding dividends). Past performance does not predict future results.

Are Intellia Therapeutics and Alpha Teknova in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons